Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft monograph: Ecnoglutide — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-047/3
Series
Public comment period
Version
1.0
Published
05 Apr 2026
Last reviewed
05 Apr 2026
Next review
05 Apr 2027
Identifier
10.71829/cei.cp.47
Certainty
Not rated
Cycle
2026 Q1
Window
18 Jan 2026 – 01 Mar 2026
Status
Closed
Submissions
7

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-ECNOGLUTIDE-/003Dr Sigrún LavrentievEvery contributing trial shares one sponsor and the monograph does not say soAccepted
DRAFT-ECNOGLUTIDE-/006Yusuf Whitmarsh-ObiA sortable table implies a comparison the underlying data do not supportNoted, no amendment
DRAFT-ECNOGLUTIDE-/004Radoslava Palmgren-KofiAdverse event frequencies are given without the denominator or the exposure periodAccepted
DRAFT-ECNOGLUTIDE-/005Dr Amara QuaresmaDeclared interests should appear on the document rather than on a separate pageNoted, no amendment
DRAFT-ECNOGLUTIDE-/001Dr Jacinta Steenkamp-FerreiraThe monograph should state what the compound costsNot accepted
DRAFT-ECNOGLUTIDE-/002Dr Mordecai Bellingham-Ojo industryTwo factual descriptions of the sponsor's programme are inaccurateAccepted
DRAFT-ECNOGLUTIDE-/007Dr Lorcan Zaleski-MbekiThe absence of a rare harm in the trial set is presented as reassuranceAccepted
7 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted4The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part0Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment2The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-ECNOGLUTIDE-/003. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
  2. Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-ECNOGLUTIDE-/004. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.
  3. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-ECNOGLUTIDE-/002. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
  4. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-ECNOGLUTIDE-/007. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.